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wall injury in C57BIJ6J mice and ApoE-/-mice. Treatment with MEG reduced neointimal 
thickening only in C57BIJ6J mice, suggesting a selective role for iNOS. In addition, ciga- 
rette smoking and hypercholesterolemia may have a synergistic effect on oxidative 
stress response to arterial injury in mice. 
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1177-87 The Protective Effect of the T(-107)C Promoter 
Polymorphiam of the Paraoxonase Gene in Arterial 
Thrombotic Disease 
Barbara Voetsch, Kelly S. Benke, Benito P. Damasceno, Lucia H. Siqueira, Joseph 
Loscalzo, Boston University Medical Center, Boston, Massachusetts, State University of 
Campinas, Campinas, Brazil. 
Background: Approximately one-third of patients with arterial thrombotic disease do not 
have traditional cardiovascular risk factors. Serum paraoxonase (PON) is an HDL-asso- 
ciated esterase that hydrolyzes products of lipid peroxidation and prevents the oxidation 
of LDL. PON levels are significantly reduced in patients with coronary heart disease. 
Recently, two PON promoter polymorphisrns, T(-107)C and G(-624)A, were identified 
that are consistently associated with lower PON expression and activity; however, it is 
not known if these polymorphisms are a risk factor for arterial thrombotic disease. 
Methods: We studied the PON promoter genotypes and vascular risk factors of 115 
patients (63 women, mean age: 35.8 _+ 6.9 years) with a clinically and radiologically 
defined arterial ischemic stroke occurring before the age of 45 years and 117 age- and 
gender-matched controls. To identify the T(-107)C polymorphism, we used non-radioac- 
tive single-strand conformational polymorphism analysis of a 129 bp-sized fragment con- 
taining the polymorphic site. 
For detection of the G(-824)A polymorphism, a 200 bp fragment was amplified using a 
mutagenic primer, resulting in an artificial restriction site for Pvu II when the polymorphic 
G nucleotide was present. 
Results: When analyzing the PON T(-107)C polymorphism, we found that the TT geno- 
type was significantly less frequent among patients than controls (12.2% vs. 22.2%, 
P=0.041). In a logistic regression model adjusting for arterial hypertension, smoking, dia- 
betes mellitus and hyperlipoproteinemia, this association remained significant 
(P=0.0297, OR=0.41,95% CI 0.19 to 0.9). Regarding the PON G(-824)A polymorphism, 
there was no significant difference between groups (P=0.47). 
Conclusion: These findings suggest that the PON -107T allele may have a protective 
effect against arterial thrombotic disease in young adults. Studies including a larger num- 
ber of patients and analyzing the effect of PON on atherothrombosis are necessary to 
understand better the mechanistic role of these observations in the development of arte- 
rial disease in the young. 
1177-88 Variability in Inhibition of Platelet Aggregation With 
Clopidogrel and Correlation With ADP-Induced P- 
Selectin Expression on Platelets 
Michael Anaioi, Pierre Theroux, Marta Ghitescu, Richard Gallo, Many Frojmovic, 
Montreal Heart Institute, Montreal, Quebec, Canada. 
Background: Thienopyridines inhibit platelet activation and aggregation by blocking the 
ADP P2Y12 receptor. We investigated the correlation between platelet aggregation and 
activation in patients treated with clopidogrel. 
Methods: Patients (n=19) with stable angina were assessed before and after 1 week 
treatment with 75 mg of clopidogrel given daily. Blood samples were anticoagulated with 
PPACK-hirudin. Platelet aggregation (TA) in stirred platelet rich plasma (PRP) and micro- 
aggregate formation (PA) in 1:10 diluted PRP at a shear stress of 1000s "1 were studied. 
In addition, flow cytometry was used to measure platelet activation, (P-selectin for secre- 
tion; and PAC-1 for free activated GPIIb/llla) after 10 p.M ADP stimulation. 
Results: Treatment by clopidogrel significantly reduced aggregation for both TA (65-+8 vs. 
45+15%, p<0.0001 ) and PA (84+8 vs. 49_+18 %, p<0.0001 ). Inhibition varied widely, from 
0 to 65% for TA; and from 0 to 70% for PA. Clopidogrel significantly decreased P-selectin 
expression (40±15 vs. 14±8%, p<0.0001) as well as PAC-1 binding (60±30 vs. 23+~?.0, 
p<0.001), By Linear regression analysis the magnitude of inhibition of platelet aggrega- 
tion correlated weakly with PAC-1 levels (R-square=0.17, p=0.08 for both TA and PA), 
but strongly with inhibition of P-selectin expression (R-square=0.28, p<0.02 and R- 
square=0.40, p<0.004, respectively). When inhibition of aggregation attained levels 
greater than 30% for TA and 25% for PA, P-selectin was always expressed by less than 
20% of platelets. 
Conclusion: Inhibition of platelet aggregation by clopidogrel was found to be highly vari- 
able. Inhibition may depend less on reduced free activated GPIIb/llla, where few recep- 
tors may be required to support aggregation, and more on reduced secreted adhesive 
ligands, Determination of P-selectin may be helpful to assess the anti-aggregant efficacy 
of clopidogrel. 
1177-89 The Relationship Between Serotonin 2A Receptor Gene 
Polymorphiems and Serotonin Induced Platelet 
Aggregation 
Masakatsu Shirnizu. Hozuka Akita, Nobuyuki Shiga, Eiji Takai, Chikao Iwai, Yoshitomo 
Miyamoto, Yukie Jyoukei, Shunichi Kumagai, Masayoshi Hashimoto, Mitsuhiro 
Yokoyama, Division of Cardiovascular and Respiratory Medicine, Kobe University 
Graduate School of Medicine, Kobe, Japan, Division of General Medical Science, Kobe 
University Graduate School of Medicine, Kobe, Japan. 
Background: Serotonin (5-HT) induces platelet aggregation (PA) and increases the vas- 
cular tonus through 5-HT2A receptor activation. Recently two common polymorphisms in 
the 6-HT2A receptor gene, T102C in exon 1 and -1438NG in the promoter, was identi- 
fied. We and others showed that these polymorphisms were associated with myocardial 
infarction or psychological disorder, However, these functional significance remains 
unknown. 
Methods: We investigated 5-HT2A receptor gene polymorphisms by PCR-RFLP and PA 
by using a novel laser-light scattering method in 33 young healthy volunteers (mean age 
26.4_+1.5SD). PA was induced by 5-HT 0.3, 1.0~M and ADP 0.1, 0.3HM, and evaluated 
by the peak of small aggregation counts. 
Results: (1)T102C polymorphism: The peak of PA induced by 5-HT in TT genotype was 
significantly higher compared with TC and CC genotype (Table), However, this polymor- 
phism did not influence ADP-induced PA. 5-HT concentration in platelet rich plasma 
(PRP) was not different between 2 groups. 
(2)-1438A/G polymorphism: A allele frequencies were 0.59 (AA: n=9, AG: n=21, GG: 
n=3). 5-HT-induced PA was not different between 2 groups (AA vs. AG+GG: 5-HT 0.31~M; 
30.8+11.4SEMx103 vs. 21.5+6.6SEM×103, NS, 5-HT 1.0~M;128.7+17.6SEM×103 vs. 
90.9~_12.2SEM×103, NS ). In addition, this did not influence ADP-induced PA. 
Conclusion: The T102C polymorphism was associated with 5-HT-induced PA, but the - 
1438A/G was not. This is the first report demonstrating the functional significance of the 
T102C polymorphism. 
T1O2C polymorphlsm, platelet aggregation, end 5-HT concentration in PRP 
TT(n=5) TC+CC(n=22+6) p 
5-HT 0.311M, x103 51.2±15.1 19.2±5.8 <0.05 
5-HT 1 .OHM, ×103 168.0±10.2 89.3±10.6 <0.005 
ADP 0.1~M, xl03 15.5±6.7 15.8¢5.4 NS 
ADP 0.3~M, xl03 161.2±25.9 92.7±14.3 NS 
5-HT in PRP, I~g/ml 0.28±0.01 0.26±0.02 NS 
1177-90 Increased Tissue Plasminogen Activator Antigen Is 
Predictive of Cardiovascular Events in the Veterans 
Affairs HDL Intervention Trial (VA-HIT) 
Geoffrev H. Taller, Sander J. Robins, Dorothea Collins, Izabela Lipinska, Prakash C. 
Deedwania, Hanna C. Rubins, Royal North Shore Hospital, Sydney, Australia. 
Background: Hemostatic factors have been shown to be predictive of future cardiovascu- 
lar disease events (CVD), although this has not been well studied in patients with known 
CVD and low HDL-CholesteroL 
Methods: We prospectively studied 829 subjects who were enrolled in the Veterans 
Affairs HDL Intervention Trial (VA-HIT). Enrolment criteria included known CVD and low 
HDL-cholesteroL Tissue plasminogen activator (TPA) antigen, factor VII antigen and 
fibrinogen were determined at baseline and after 1 year of therapy with placebo or gemfi- 
brozil. There was no effect of gemfibrozil on these measures of hemostasis. Thus, data 
from the gemfibrozil and placebo arms were combined. 
Results: During follow-up (median 5.1 years),140 patients had as a first event nonfatal MI 
or cardiac death. Relative risks (RR) were determined by multivariate Cox models, 
adjusting for age, hypertension, diabetes, smoking, body mass index, compliance and 
treatment. 
Results: Higher tPA antigen levels were associated with increased cardiovascular risk 
(4.7% for each unit tPA increase), whereas fibrinogen and factor VII were not significant 
predictors. 
Conclusion: Reduced fibrinolytic potential, as evidenced by increased tPA antigen levels, 
was a significant predictor of cardiovascular events in patients with known CVD and low 
HDL. Measurement of tPA may provide prognostic value in this subjects. Strategies to 
improve fibrinolytic potential in this population warrant further investigation. 
MI/Cardiac Death 
RR 95% CI p-value 
tPA antigen (ng/ml) 1.047 1.004-1.092 0.03 
Factor VII antigen (%) 1.002 0.990-1.014 0.78 
Fibrinogen (mg/dl) 0.999 0.996-1.002 0.90 
1177-91 Investigation of Thrombocytopenla In Individuals 
Receiving GPIIb-Illa Antagonist Therapy 
Lisa K. Jenninos. Steven Slack, Shila Cholera, Melanie White, Lou Ann Keith, Mary V. 
Jacoski, Sophie Combe, University of Tennessee Health Science Center, Memphis, 
Tennessee. 
Background: The use of GPfib-Illa antagonists for treatment of acute coronary syn- 
dromes continues to rise, as studies consistently demonstrate a significant benefit in 
reducing ischemic endpoints, Thrombocytopenia (TCP) is an infrequent, yet serious 
potential side effect of GPIIb-Illa antagonists. Little is known about the mechanism 
behind its development, therefore it is often impossible to predict which patient is at risk 
at the treatment onset. These patients are also concurrently treated with several drugs 
